ArticleMikrochimica acta2025
Self-reduced Pd nanoparticles on NiMn-LDHs with superior catalytic activity for signal amplification in electrochemical aptasensing of Mycobacterium tuberculosis ESAT-6 antigen.
Article in Mikrochimica acta, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- (Cu-S)Mikrochimica acta · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Non-sputum-based diagnostic tests for tuberculosis (TB) are critical to global TB control. Herein, we developed an electrochemical aptasensor for detecting the ESAT-6 antigen of Mycobacterium tuberculosis (MTB) in human serum, using NiMn-layered double hydroxides@palladium nanoparticles (NiMn-LDHs@PdNPs) as a high-performance signal enhancer. NiMn-LDHs@PdNPs were synthesized via spontaneous in situ reduction, which requires no toxic reagents or complex equipment. This design not only addresses the limitations of insufficient active sites and slow electron transfer in layered double hydroxides (LDHs) but also mitigates the agglomeration tendency of palladium (Pd) nanoparticles, thereby enabling synergistic peroxidase-like activity and, importantly, relative spatial decoupling of recognition sites from catalytic sites. Functionalization with aptamers targeting the MTB ESAT-6 antigen did not significantly impair its catalytic activity. Employing a classic sandwich configuration, the aptasensor exhibited a wide linear detection range of 75 pg/mL to 10 ng/mL with a low limit of detection (LOD) of 0.629 pg/mL, alongside excellent specificity, stability, and reproducibility. In clinical validation, it successfully distinguished 14 TB patients from 14 healthy donors with 100% accuracy and outperformed enzyme-linked immunosorbent assay (ELISA). This work provides a high-performance non-sputum-based tool for TB diagnosis and advances the design of nanozyme-based biosensors.
Indexed as
Identifiers
41339596What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.